Global Transdermal Testosterone Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Transdermal Testosterone Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Transdermal Testosterone contains testosterone. It is used for hormone replacement in men who are not able to produce enough testosterone (e.g., hypogonadism). This medication is absorbed through the skin, enters your bloodstream, and helps your body reach normal testosterone levels.
Transdermal Testosterone report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Transdermal Testosterone market is projected to reach US$ 923.9 million in 2029, increasing from US$ 589 million in 2022, with the CAGR of 7.4% during the period of 2024 to 2029. Demand from Primary Hypogonadism and Hypogonadotropic Hypogonadism are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Transdermal Testosterone industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Transdermal Testosterone key manufacturers include AbbVie, Teva, Perrigo, Endo Pharmaceuticals, Acerus Pharmaceuticals, Lupin, Dr. Reddy's Laboratories, Upsher-Smith Laboratories and Allergan, etc. AbbVie, Teva, Perrigo are top 3 players and held % sales share in total in 2022.
Transdermal Testosterone can be divided into Gel and Patch, etc. Gel is the mainstream product in the market, accounting for % sales share globally in 2022.
Transdermal Testosterone is widely used in various fields, such as Primary Hypogonadism, Hypogonadotropic Hypogonadism and Late-Onset Hypogonadism,, etc. Primary Hypogonadism provides greatest supports to the Transdermal Testosterone industry development. In 2022, global % sales of Transdermal Testosterone went into Primary Hypogonadism filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Transdermal Testosterone market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
AbbVie
Teva
Perrigo
Endo Pharmaceuticals
Acerus Pharmaceuticals
Lupin
Dr. Reddy's Laboratories
Upsher-Smith Laboratories
Allergan
Cipla Inc.
Segment by Type
Gel
Patch
Primary Hypogonadism
Hypogonadotropic Hypogonadism
Late-Onset Hypogonadism
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Transdermal Testosterone market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Transdermal Testosterone, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Transdermal Testosterone industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Transdermal Testosterone in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Transdermal Testosterone introduction, etc. Transdermal Testosterone Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports Conclusions of Transdermal Testosterone market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Transdermal Testosterone report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Transdermal Testosterone market is projected to reach US$ 923.9 million in 2029, increasing from US$ 589 million in 2022, with the CAGR of 7.4% during the period of 2024 to 2029. Demand from Primary Hypogonadism and Hypogonadotropic Hypogonadism are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Transdermal Testosterone industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Transdermal Testosterone key manufacturers include AbbVie, Teva, Perrigo, Endo Pharmaceuticals, Acerus Pharmaceuticals, Lupin, Dr. Reddy's Laboratories, Upsher-Smith Laboratories and Allergan, etc. AbbVie, Teva, Perrigo are top 3 players and held % sales share in total in 2022.
Transdermal Testosterone can be divided into Gel and Patch, etc. Gel is the mainstream product in the market, accounting for % sales share globally in 2022.
Transdermal Testosterone is widely used in various fields, such as Primary Hypogonadism, Hypogonadotropic Hypogonadism and Late-Onset Hypogonadism,, etc. Primary Hypogonadism provides greatest supports to the Transdermal Testosterone industry development. In 2022, global % sales of Transdermal Testosterone went into Primary Hypogonadism filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Transdermal Testosterone market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
AbbVie
Teva
Perrigo
Endo Pharmaceuticals
Acerus Pharmaceuticals
Lupin
Dr. Reddy's Laboratories
Upsher-Smith Laboratories
Allergan
Cipla Inc.
Segment by Type
Gel
Patch
Segment by Application
Primary Hypogonadism
Hypogonadotropic Hypogonadism
Late-Onset Hypogonadism
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Transdermal Testosterone market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Transdermal Testosterone, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Transdermal Testosterone industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Transdermal Testosterone in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Transdermal Testosterone introduction, etc. Transdermal Testosterone Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports Conclusions of Transdermal Testosterone market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices